Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death: Implications for therapy of parkinson's disease

Biochemistry

Volumn 49, Issue 12, 2010, Pages 2715-2724

  Sabens, Elizabeth A ^a   Distler, Anne M ^a,c   Mieyal, John J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c Cuyahoga Community College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELLULAR CONTENT; CHEMICAL INHIBITION; CONCENTRATION-DEPENDENT; DOPAMINERGIC NEURONS; DOSE-DEPENDENT; GLUTATHIONE DISULFIDE; GLUTATHIONES; ISOLATED ENZYMES; LEVODOPA; MITOCHONDRIAL DYSFUNCTION; MOLECULAR LEVELS; NEURONAL CELL; NEURONAL LOSS; NEURONAL SURVIVAL; PARKINSON'S DISEASE; PROOXIDANT; PROTEIN AGGREGATION; PROTEIN CONTENTS; SULFHYDRYL; THIOL-DISULFIDE; THIOREDOXIN REDUCTASE; THIOREDOXINS;

BODY FLUIDS; CATALYSTS; CELL DEATH; ENZYME ACTIVITY; ENZYMES; NEURONS;

ENZYME INHIBITION;

AURANOFIN; CYSTEINE; DISULFIDE; DOPAQUINONE; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; LEVODOPA; OXIDOREDUCTASE; QUINONE DERIVATIVE; THIOL; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ADDUCTION; APOPTOSIS; ARTICLE; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME INACTIVATION; HOMEOSTASIS; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ANTIOXIDANTS; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; DISULFIDES; DOPAMINE; HOMEOSTASIS; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE; PROTEIN CARBONYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; THIOREDOXINS;

EID: 77949787683     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi9018658     Document Type: Article

References (43)

1. Riedlerer, P. F. (2004) Views on neurodegeneration as a basis for neuroprotective strategies. Med. Sci. Monit. 10, RA287-RA290.
2. Maguire-Zeiss, K. A., Short, D. W., and Federoff, H. J. (2005) Synuclein, dopamine and oxidative stress: Co-conspirators in Parkinson's disease? Brain Res. Mol. Brain Res. 134, 18-23.
3. Olanow, C. W., and Tatton, W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144.
4. Walkinshaw, G., and Waters, C. M. (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95, 2458-2464.
5. Asanuma, M., Miyazaki, I., az-Corrales, F. J., and Ogawa, N. (2004) Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxininduced parkinsonism. Acta Med. Okayama 58, 221-233.
6. Spencer, J. P., Jenner, A., Butler, J., Aruoma, O. I., Dexter, D. T., Jenner, P., and Halliwell, B. (1996) Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: Implications for Parkinson's disease. Free Radical Res. 24, 95-105.
7. Ahlskog, J. E. (2007) Beating a dead horse: Dopamine and Parkinson disease. Neurology 69, 1701-1711.
8. Legros, H., Dingeval, M. G., Janin, F., Costentin, J., and Bonnet, J. J. (2004) Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25, 365-375.
9. Klegeris, A., and McGeer, P. L. (2000) R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol. 166, 458-464.
10. Chrestensen, C. A., Eckman, C. B., Starke, D. W., and Mieyal, J. J. (1995) Cloning, expression and characterization of human thioltransferase (glutaredoxin) in E. coli 1. FEBS Lett. 374, 25-28.
11. Chrestensen, C. A., Starke, D. W., and Mieyal, J. J. (2000) Acute cadmium exposure inactivates thioltransferase (glutaredoxin), inhibits intracellular reduction of protein-glutathionyl-mixed disulfides, and initiates apoptosis. J. Biol. Chem. 275, 26556-26565.
12. Jao, S. C., English Ospina, S. M., Berdis, A. J., Starke, D. W., Post, C.B., and Mieyal, J. J. (2006) Computational and mutational analysis of human glutaredoxin (thioltransferase): Probing the molecular basis of the low pKa of cysteine 22 and its role in catalysis. Biochemistry 45, 4785-4796.
13. Gallogly, M. M., Starke, D. W., Leonberg, A. K., English Ospina, S. M., Gillenberger, S., and Mieyal, J. J. (2007) Correspondence of the Catalytic Mechanisms of the Mammalian Glutaredoxin 1 and Glutaredoxin 2 Enzymes: Functional Implications.
14. Starke, D. W., Chen, Y., Bapna, C. P., Lesnefsky, E. J., and Mieyal, J. J. (1997) Sensitivity of protein sulfhydryl repair enzymes to oxidative stress. Free Radical Biol. Med. 23, 373-384.
15. Carlberg, I., and Mannervik, B. (1985) Glutathione reductase. Meth-ods Enzymol. 113, 484-490.
16. Amer, E. S., Zhong, L., and Holmgren, A. (1999) Preparation and assay of mammalian thioredoxin and thioredoxin reductase. Methods Enzymol. 300, 226-239.
17. Gravina, S. A. (1993) Characterization and Kinetic Mechanism of Thioltransferase, Ph.D. Thesis, Case Western Reserve University, Cleveland, OH.
18. Perry, T. L., Godin, D. V., and Hansen, S. (1982) Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci. Lett. 33, 305-310.
19. Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H., and Marsden, C. D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32 (Suppl.), S82-S87.
20. Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., and Marsden, C. D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355.
21. Ziegler, D. M. (1985) Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Annu. Rev. Biochem. 54, 305-329.
22. Mieyal, J. J., Srinivasan, U., Starke, D. W., Gravina, S. A., and Mieyal, P. A. (1995) in Glutathionyl Specificity of the Thioltransferases: Mechanistic and Physiological Implications (Packer, L., and Cadenas, E., Eds.) pp 305-372, Marcel Dekker, Inc., New York.
23. Sabens, E. A., and Mieyal, J. J. (2009) Glutaredoxin and Thioredoxin Enzyme Systems: Catalytic Mechanisms and Physiological Functions. In Glutathione and Sulfer Amino Acids in Human Health and Disease (Masella, R., and Mazza, G., Eds.) pp 121-156, John Wiley and Sons, Inc., Hoboken, NJ.
24. Jacob, C., Knight, I., and Winyard, P. G. (2006) Aspects of the biological redox chemistry of cysteine: From simple redox responses to sophisticated signalling pathways. Biol. Chem. 387,1385-1397.
25. Mieyal, J. J., Gallogly, M. M., Qanungo, S., Sabens, E. A., and Shelton, M. D. (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid. Redox Signaling 10, 1941-1988.
26. Cox, A. G., Brown, K. K., Amer, E. S., and Hampton, M. B. (2008) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem. Pharmacol. 76, 1097-1109.
27. Gandin, V., Fernandes, A. P., Rigobello, M. P., Dani, B., Sorrentino, F., Tisato, F., Bjomstedt, M., Bindoli, A., Sturaro, A., Rella, R., and Marzano, C. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101.
28. Brunton, L., Lazo, J., and Parker, K. (2010) The Pharmacological Basis of Therapeutics, McGraw Hill, New York.
29. Srinivasan, U., Bala, A., Jao, S. C., Starke, D. W., Jordan, T. W., and Mieyal, J. J. (2006) Selective inactivation of glutaredoxin by sporidesmin and other epidithiopiperazinediones. Biochemistry 45, 8978-8987.
30. Srinivasan, U., Mieyal, P. A., and Mieyal, J. J. (1997) pH profiles indicative of rate-limiting nucleophilic displacement in thioltransferase catalysis. Biochemistry 36, 3199-3206.
31. Van, L. V., Mishizen, A. J., Cascio, M., and Hastings, T. G. (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 34, 487-500.
32. Klatt, P., Molina, E. P., De Lacoba, M. G., Padilla, C. A., MartinezGalesteo, E., Barcena, J. A., and Lamas, S. (1999) Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J. 13, 1481-1490.
33. Wang, J., Tekle, E., Oubrahim, H., Mieyal, J. J., Stadtman, E. R., and Chock, P. B. (2003) Stable and controllable RNA interference: Investigating the physiological function of glutathionylated actin. Proc. Natl. Acad. Sci. U.S.A. 100, 5103-5106.
34. Klatt, P., Molina, E. P., and Lamas, S. (1999) Nitric oxide inhibits c-Jun DNA binding by specifically targeted S-glutathionylation. J. Biol. Chem. 274, 15857-15864.
35. Wang, J., Boja, E. S., Tan, W., Tekle, E., Fales, H. M., English, S., Mieyal, J. J., and Chock, P. B. (2001) Reversible glutathionylation regulates actin polymerization in A431 cells. J. Biol. Chem. 276, 47763-47766.
36. Qanungo, S., Starke, D. W., Pai, H. V., Mieyal, J. J., and Nieminen, A. L. (2007) Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NFkB. J. Biol. Chem. 282, 18427-18436.
37. Saeed, U., Durgadoss, L., Valli, R. K., Joshi, D. C., Joshi, P. G., and Ravindranath, V. (2008) Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: Implication in neurodegenerative diseases. PLoS One 3, e2459.
38. Kenchappa, R. S., Diwakar, L., Annepu, J., and Ravindranath, V. (2004) Estrogen and neuroprotection: Higher constitutive expression of glutaredoxin in female mice offers protection against MPTPmediated neurodegeneration. FASEB J. 18, 1102-1104.
39. Casagrande, S., Bonetto, V., Fratelli, M., Gianazza, E., Eberini, I., Massignan, T., Salmona, M., Chang, G., Holmgren, A., and Ghezzi, P. (2002) Glutathionylation of human thioredoxin: A possible crosstalk between the glutathione and thioredoxin systems. Proc. Natl. Acad. Sci. U.S.A. 99, 9745-9749.
40. Wang, J., Jiang, H., and Xie, J. X. (2004) Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem. Res. 29, 2239-2243.
41. Borisenko, G. G., Kagan, V. E., Hsia, C. J., and Schor, N. F. (2000) Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". Biochemistry 39, 3392-3400.
42. Masutani, H., Bai, J., Kim, Y. C., and Yodoi, J. (2004) Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection. Mol. Neurobiol. 29, 229-242.
43. Rundlof, A. K., and Amer, E. S. (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signaling 6, 41-52.